Predicting the long-term risk of HIV exposure by cryoprecipitate

Haemophilia

Volumn 6, Issue SUPPL. 1, 2000, Pages 128-132

  Evatt, B ^a   Austin, H ^b   Leon, G ^c   Ruiz Saez A ^c   De Bosch, N ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY   (United States)

^c Centro Nacional de Hemofilia   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; BLOOD CLOTTING FACTOR 8; CRYOPRECIPITATE COAGULUM; FIBRINOGEN; FIBRONECTIN;

ARTICLE; BLOOD DONOR; CRYOPRECIPITATE; HEMOPHILIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RISK; UNITED STATES; VENEZUELA; VIRUS TRANSMISSION; BLOOD TRANSFUSION; DISEASE TRANSMISSION; DRUG CONTAMINATION; HEMOPHILIA A; INCIDENCE; RISK FACTOR; THEORETICAL MODEL; VIROLOGY;

BLOOD DONORS; BLOOD TRANSFUSION; DRUG CONTAMINATION; FACTOR VIII; FIBRINOGEN; FIBRONECTINS; HEMOPHILIA A; HIV INFECTIONS; HUMANS; INCIDENCE; MODELS, THEORETICAL; RISK FACTORS; UNITED STATES; VENEZUELA;

EID: 0034223142     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2000.00057.x     Document Type: Article

References (12)

1. Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia 1998; 4: 474-80.
2. Lackritz EM, Satten GA, Aberle-Grasse J et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. New Engl J Med. 1995; 333(26): 1721-5.
3. Centers for Disease Control and Prevention. National HIV. Serosurveillance Summary. Results through 1992, 3. Atlanta, GA. U.S. Department of Health and Human Services, 1994.
4. Busch MP et al. Estimation of HIV incidence in US blood donors using a novel detuned anti-HIV EIA test strategy. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1-5, 1998.
5. Busch MP, Lee LLJ, Satten GA et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995; 35: 91-7.
6. Kleinman SH, Niland JC, Azen SP et al. Prevalence of antibodies to human immunodeficiency virus type 1 among blood donors prior to screening. Transfusion 1989; 29(7): 572-80.
7. Linden JV, Kaplan HS. Transfusion errors: causes and effects. Transfus Med Rev 1994; 8:1 69-83.
8. Linden JV. Error contributes to the risk of transmissible disease. Transfusion 1994; 34: 1016.
9. Leon G, Hernández T, Arias G, Celis S, Acosta V, Semprun O, Lugo M. VIH y donantes de sangre: pasado, presente y futuro. Sangre 1993; 39:(1) 15-21.
10. Leon G, Hernández T, Quiróz AM, Maio A, Garcia L. Como reducir la prevalencia de donantes de sangre VIH positivosM. Investigación Clínica (in press).
11. Kendall MG, Stuart A. The Advanced Theory of Statistics, 3rd edition. New York: Hafner Publishing Company, 1969; 1: 264.
12. Bird A, Isarangkura P, Almagro D, Gonzaga A, Srivastava A. Factor concentrates for haemophilia in the developing world. Haemophilia 1998; 4: 481-5.